Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024
Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024
GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting of the American Association for the Study of Liver Diseases. The data showed reductions in multiple classes of inflammatory lipid species associated with adverse cardiovascular outcomes. Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist in development for the treatment of MASH and obesity.Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
皮安维杜肽每周皮下注射剂量导致心脏炎症、肝炎炎症和动脉粥样硬化脂质的显著降低。
Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome
研究结果支持皮安维杜肽对代谢功能失调相关脂肪肝（MASH）并发症，包括动脉硬化、心脏病和代谢综合征的潜在益处。
Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025
皮安维杜肽当前正在IMPACt评估中，这是针对MASH患者的第20亿期试验；数据公布预计在2025年第二季度。
GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting of the American Association for the Study of Liver Diseases. The data showed reductions in multiple classes of inflammatory lipid species associated with adverse cardiovascular outcomes. Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist in development for the treatment of MASH and obesity.
马里兰盖瑟斯堡，2024年11月15日（环球新闻社）—Altimmune, Inc.（纳斯达克：ALT），一家临床阶段生物制药公司，今天在美国肝病研究协会肝病学讨论会上展示了其关于皮安维杜肽在代谢功能失调相关肥胖性脂肪肝（MASLD）12周第10亿期试验的新数据。数据显示，与不良心血管结果相关的多种炎症脂质种类减少。皮安维杜肽是一种用于治疗MASH和肥胖症的平衡GLP-1/胰高血糖素受体激动剂。
The new data were derived from an analysis of plasma samples from subjects who completed a randomized placebo-controlled Phase 1b trial of pemvidutide in subjects with overweight or obesity and MASLD. In the Phase 1b clinical trial, 94 subjects with obesity or overweight and liver fat content (LFC) ≥10% were dosed 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. In this study, pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment.
新数据来源于对完成了皮安维杜肽在超重或肥胖以及MASLD患者中随机安慰剂对照第10亿期试验的受试者血浆样本的分析。在第10亿期临床试验中，94名超重或肥胖以及肝脂含量（LFC）≥10%的受试者被1:1:1:1地分配到每周一次皮下注射的皮安维杜肽（1.2毫克、1.8毫克和2.4毫克）或安慰剂治疗12周。在这项研究中，与基线相比，皮安维杜肽可将LFC减少高达68.5%，并在治疗12周后将总胆固醇和三酰甘油分别降低高达12.2%和44.6%。
The goal of the study was to characterize changes in the lipid profile of patients before and after treatment with pemvidutide. In this study of 50 subjects, treatment with pemvidutide was shown to reduce plasma concentrations of atherogenic lipoproteins and lipotoxic lipid classes associated with MASH and implicated in cardiovascular and atherosclerotic disease. In particular, a rapid and significant reduction in small atherogenic LDL particles was observed in the 1.8 mg and 2.4 mg dose groups compared to placebo.
该研究的目标是描述接受皮安维杜肽治疗前后患者的脂质画像变化。在这项涉及50名受试者的研究中，皮安维杜肽治疗显示可以降低与MASH相关并涉及心血管和动脉粥样硬化疾病的致病脂质类别的血浆浓度。特别地，与安慰剂相比，1.8毫克和2.4毫克剂量组中小型致病性LDL颗粒迅速且显著减少。
